YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Calidi Biotherapeutics (CLDI [https://seekingalpha.com/symbol/CLDI]) announced on Friday that it received a NYSE American compliance notice for failing to meet the exchange’s $4M minimum stockholders’ equity requirement. * The notice [ht…
Calidi Biotherapeutics, Inc SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, toda…
(RTTNews) - Calidi Biotherapeutics, Inc. (CLDI), a biotechnology company, announced a proposed 1-for-16 reverse stock split of its outstanding common stock, effective July 31, 2026. The company's common stock will begin trading on a split-…
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effe…
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appoint…
(RTTNews) - Calidi Biotherapeutics, Inc. (CLDI) announced the appointment of Corsee Sanders as an independent director on the company's Board of Directors, effective from June 17, 2026. Sanders previously held several leadership positions…
Calidi Biotherapeutics, Inc Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biothera…
On May 14, 2026, Finepoint Capital LP disclosed a first-quarter buy of 684,829 RXO(NYSE:RXO) shares, an estimated $10.05 million trade based on quarterly average pricing. What happened According to a SEC filing dated May 14, 2026, Finepoin…
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today advised that its Financial…
(RTTNews) - Calidi Biotherapeutics Inc. (CLDI), a clinical-stage biotechnology company, released on Monday new data on the approach of simultaneous T-cell activation and expression of T-cell engagers in the tumor microenvironment at the 20…
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and analytical approaches fo…
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of…
(RTTNews) - Calidi Biotherapeutics, Inc.(CLDI), a biotechnology firm, announced the pricing of its underwritten public offering of 10.52 million units at a price of $0.50 per unit. Each unit has one share of common stock or a pre-funded wa…
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it intends…
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deli…
Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can effectively express genetic medicin…
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deli…
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT NBY [https…
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT NBY [https://www.chartmill.com/stock/quote/NBY/profile] 74.8% Investors celebrated as…
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT NBY [https://www.chartmill.com/stock/quote/NBY/profi…
SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deli…
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT SNGX [https://www.…
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT SNGX [https://www.chartmill.com/stock/quo…
* Calidi Biotherapics (NYSE:CLDI [https://seekingalpha.com/symbol/CLDI]) filed to sell 1.2M common stock units. * Filing [https://seekingalpha.com/filing/10314729] MORE ON CALIDI BIOTHERAPEUTICS * Seeking Alpha’s Quant Rating on Calidi Bio…
* Calidi Biotherapeutics press release [https://seekingalpha.com/pr/20195263-calidi-biotherapeutics-reports-second-quarter-2025-financial-results-and-recent-operational] (NYSE:CLDI [https://seekingalpha.com/symbol/CLDI]): Q2 GAAP EPS of -$…
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane…
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action! [mostactive] MOST ACTIVE STOCKS TICKER CHANGE COMMENT GIBO [https://www.chartmill.com/stock/quote/GIBO/profile] 44.2% 569.46M shares o…
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT STAI [https://www.chartmill.com/stock/quote/STAI/p…
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT SLRX [ht…
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT ANGH [https:…
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT AIM [https://www.chartmill.com/stock/quote/AIM/profile]…
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT HTOOW [https://www.chartmill.com/stock/…
* Calidi Biotherapeutics (NYSE:CLDI [https://seekingalpha.com/symbol/CLDI]) said on Friday that it will effect a reverse stock split [https://seekingalpha.com/pr/20178578-calidi-announces-reverse-stock-split-expected-to-begin-trading-on-a-…
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deli…
SAN DIEGO - Calidi Biotherapeutics, Inc. (NYSE American:CLDI), currently trading at $1.09 per share with a market capitalization of $11.25 million, announced Wednesday it has entered into a definitive agreement for the immediate exercise o…
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 mi…